The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 1, 2018

Primary Completion Date

December 15, 2022

Study Completion Date

December 15, 2022

Conditions

Atopic DermatitisAtopic Dermatitis Eczema

Interventions

DRUG

Dupilumab

Dupilumab treatment

Trial Locations (1)

UCSF Psoriasis and Skin Treatment Center, San Francisco

All Listed Sponsors

collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

University of California, San Francisco

OTHER

NCT03667014 - The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients | Biotech Hunter | Biotech Hunter